Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€0.75

€0.75

2.610%
0.02
2.610%
€18.62
 
18.04.24 / Tradegate WKN: A2JPE7 / Symbol: KZR / Name: Kezar Life Sciences / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Kezar Life Sciences Stock

There is an upward development for Kezar Life Sciences compared to yesterday, with an increase of €0.020 (2.610%).
Currently there is a rather positive sentiment for Kezar Life Sciences with 4 Buy predictions and 0 Sell predictions.
Based on the current price of 0.75 € the target price of 18 € shows a potential of 2316.11% for Kezar Life Sciences which would more than double the current price.
For the coming years our community has positive and negative things to say abot the Kezar Life Sciences stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "General Risks" there were negative voices in the community.

Pros and Cons of Kezar Life Sciences in the next few years

Pros
?
B****
?
G***** c******* t* c**********
?
S********** s********
Cons
?
C******** o* t** e**********
?
M***** P*******
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Kezar Life Sciences vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Kezar Life Sciences 2.610% 0.000% -17.680% -67.325% -14.368% -85.248% -
Ardelyx Inc. 0.130% -5.482% -15.972% 32.578% 3.218% -12.905% -
Salarius Pharmaceuticals Inc. 0.950% -0.935% -18.462% -68.120% -23.604% -98.261% -99.994%
Brainstorm Cell 1.170% -0.896% -1.485% -81.710% 114.440% -80.717% -

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-04-15

Upon examining the financial statements of Kezar Life Sciences (KZR), a company operating in the Biotechnology & Medical Research industry, it's clear that the firm is going through a phase of consistent investment in research and development. The company has shown growth in assets and has managed to secure financing to fund its operations. However, there is considerable concern arising from its lack of revenue and growing net losses.

Growing Assets: The total assets for the company have consistently increased over the past three years (2020-2022), amounting to $151,842,000 in 2020 and reaching $299,568,000 by 2022. This growth in assets may indicate that Kezar Life Sciences is making strategic investments to advance its operations and research.

Increasing Investment in Research and Development: Kezar Life Sciences has been making significant investments in R&D, with expenditures rising from $30,981,000 in 2020 to $51,009,000 in 2022. This growing investment in research and development could signal the company's dedication to developing innovative therapies and treatments, which is crucial in the Biotechnology & Medical Research Industry.

Comments

Prediction Buy
Perf. (%) -5.59%
Target price 18.422
Change
Ends at 04.12.24

Kezar Life Sciences, Inc. (NASDAQ: KZR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
Ratings data for KZR provided by MarketBeat
Show more

Prediction Buy
Perf. (%) -8.75%
Target price 18.268
Change
Ends at 27.11.24

Kezar Life Sciences, Inc. (NASDAQ: KZR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
Ratings data for KZR provided by MarketBeat
Show more

Prediction Buy
Perf. (%) -16.29%
Target price 18.898
Change
Ends at 12.10.24

Kezar Life Sciences, Inc. (NASDAQ: KZR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
Ratings data for KZR provided by MarketBeat
Show more